Article citationsMore>>

Musengimana, G., Tuyishime, E., Kiromera, A., Malamba, S.S., Mulindabigwi, A., Habimana, M.R., Baribwira, C., Ribakare, M., Habimana, S.D., DeVos, J., Mwesigwa, R.C.N., Kayirangwa, E., Semuhore, J.M., Rwibasira, G.N., Suthar, A.B. and Remera, E. (2022) Acquired HIV Drug Resistance among Adults Living with HIV Receiving First-Line Antiretroviral Therapy in Rwanda: A Cross-Sectional Nationally Representative Survey. Antiviral Therapy, 27.
https://doi.org/10.1177/13596535221102690

has been cited by the following article:

• TITLE: Detection of ARV-Resistant Mutants in HIV-1-Infected Individuals in a Context of Systematic Switching to an Association Based on Dolutegravir in Abidjan, Côte d’Ivoire

  AUTHORS: Odegue Kpadraux Danielle, Kakou-Ngazoa Solange, Dechi Jean-Jacques Renaud, Diallo Zelica, Sina Kouamé Mireille, Sylla Aboubacar, Tossea Koui Stéphane, Kouakou Venance, Adagba Marius, Apia N’Chouo Kouamé Basile, Touré Offianan André, Dosso Mireille

  KEYWORDS: Resistant Mutants, Dolutegravir, HIV-1, Antiretrovirals, Côte d’Ivoire

  JOURNAL NAME: American Journal of Molecular Biology, Vol.14 No.3, June 14, 2024

  ABSTRACT: The emergence of antiretroviral resistance mutations represents a major threat to the achievement of national and global goals for the elimination of HIV-1 infection. The global strategy in 2019 in Côte d'Ivoire is a new national policy for the management of people living with HIV with the administration of dolutegravir (DTG)-based fixed-dose combination. The aim of our study was to evaluate HIV-1 resistance to antiretrovirals (ARVs) in infected adult subjects in Côte d’Ivoire in the context of a systematic switch to a DTG-based combination. Between February 2022 and October 2023, a cross-sectional survey with random sampling was conducted in 06 services caring for people living with HIV. A total of 139 participants were included in the study. Adults with a viral load ≥ 1000 copies/mL were tested for HIV-1 ARV resistance mutations. Molecular analyses were performed using protocol of ANRS-MIE (National Agency for Research on AIDS and emerging infectious diseases). The interpretation is performed by HIVGRAD (https://www.hiv-grade.de/cms/grade/). The frequencies of HIV-1 resistance to non-nucleotide reverse transcriptase inhibitors (NNRTIs), nucleotide reverse transcriptase inhibitors (NRTIs), integrase inhibitors (IINTs) and protease inhibitors (PIs) were 82%, 73%, 19% and 11% respectively. The main mutations observed in the different classes were K103N (45%), M184V (64%), E157Q (19%) and L10V/M46I/A71V/I54V (6%) respectively. This study reveals the emergence of resistance to DTG-based fixed-dose combinations, favored by high rates of resistance to NRTIs and NNRTIs. This finding underlines the need for enhanced viral load monitoring and HIV-1 genotyping tests to guide the choice of NRTIs for combination therapy. In addition, monitoring for mutations to second-generation NRTIs is essential, given the scale-up of DTG-based regimens currently underway in Côte d’Ivoire.